If you are not happy with the results below please do another search
Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to Covid-19.
People who have had Covid-19 are highly unlikely to contract the disease again for at least six months after their first infection, according to a British study of healthcare workers on the frontline of the fight against the coronavirus pandemic.
Johnson & Johnson was ordered by a New York state judge to pay $120 million in damages to a Brooklyn woman and her husband, after she blamed her cancer on asbestos exposure from using the company’s baby powder.
Gilead’s remdesivir should not be used for patients hospitalized with Covid-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organization panel said.
The U.S. Food and Drug Administration granted Emergency Use Authorization to a combination of Eli Lilly’s and Incyte’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir as a treatment for hospitalized patients diagnosed with Covid-19 who require supplemental oxygen or ventilation.
PRECISIONeffect launched a new work-break video series – This Medical Moment – hosted by the healthcare advertising agency’s president, Carolyn Morgan.
With all the expectations for available Covid-19 vaccines based on the successful late-stage trial results reported by Pfizer/BioNTech and Moderna, the looming question is: when will the public be able to start getting the vaccines?
A new wave of mobile apps that help track exposure to the coronavirus is coming to U.S. states ahead of the holidays as public health officials bet that recently introduced features from Apple Inc. and Alphabet Inc.’s Google will significantly boost adoption and impact.
Researchers at Weill Cornell Medicine identified a specific and unique kind of immune cell activity in the lungs of Covid-19 patients that is different from the type of immune cell activity found in other respiratory infections.
Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, the company’s SVP of finance.